Skip to content

H2020FP7HORIZON

Percuros BV

Country
NLNetherlands
Defence projects
0
Projects, all programmes
27
As coordinator
13
EU contribution (CORDIS)
EUR 7,287,552
Active
2008 to 2022

Projects

27 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
CROSSBRAINDistributed and federated cross-modality actuation through advanced nanomaterials and neuromorphic learningHORIZON2022ParticipantEUR 0
GELNANODEPA gel-network depot for bringing advance strategies for skin cancerH20202021CoordinatorEUR 187,572
PIANONanoparticle-Based Imaging and Therapy of Chronic Pain in the Dorsal Root Ganglia (DRG)H20202021ParticipantEUR 210,282
cONCReTEDevelOpmeNt of Cancer RNA TherapEuticsH20202020ParticipantEUR 174,800
RISE-WELLCritical solutions for elderly well-beingH20202020ParticipantEUR 183,942
BARRICADEevolutionary platform to predict breast cancer (BC) patients outcome and response to therapyH20202020CoordinatorEUR 175,572
Gl.EXOInnovative tools to detect Glioblastoma (GBM) exosomesH20202020CoordinatorEUR 175,572
NOVA-MRINovel Applications in 19F Magnetic Resonance ImagingH20202020ParticipantEUR 213,972
BiosafetyBiosafety assays for the diagnosis and prediction of drug-related complement pathologyH20202020ParticipantEUR 200,000
BESGBioengineered exosomes based approaches for the effective treatment of non-small cell lung cancerH20202020CoordinatorEUR 175,572
SENATORStaff Exchange for Novel applications in 19f magnetic resonance imagingH20202020ParticipantEUR 202,400
PRISAR2proactive monitoring of cancer as an alternative to surgeryH20202020CoordinatorEUR 331,200
SIMICASite-selective protein-modification chemistries for antibody-drug conjugates (ADCs)H20202019ParticipantEUR 165,000
BrEXo-AptNon-invasive and accurate diagnosis and treatment of breast cancer.H20202019CoordinatorEUR 187,572
NeuroAPANeurodevelopmental outcome in offspring conceived by parents at advanced parental ageH20202019CoordinatorEUR 175,572
PAVEA nanovaccine Approach for the treatment of Pancreatic CancerH20202019ParticipantEUR 265,620
THERAPROBESBiodegradable fluorescent nanoprobes for early detection of (pre)malignant lesions of the gastrointestinal tractH20202019CoordinatorEUR 187,572
CANCERPersonalised Postoperative Immunotherapy To Improving Cancer Outcome and improving quality of lifeH20202018CoordinatorEUR 378,000
pHioniCpH and Ion Transport in Pancreatic CancerH20202018ParticipantEUR 265,620
ACORNNanoparticle-Based Therapeutic Applications and Detection of Carbon Monoxide Releasing MoleculesH20202018ParticipantEUR 215,000

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.